683 Capital Management, LLC Larimar Therapeutics, Inc. Transaction History

683 Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$4.0 - $6.68 $471,988 - $788,219	-117,997 Reduced 62.77%	70,000 $317,000
Q4 2022 Feb 14, 2023	SELL	$2.73 - $5.08 $455,721 - $848,009	-166,931 Reduced 47.03%	187,997 $776,000
Q3 2022 Nov 14, 2022	BUY	$1.53 - $3.64 $162,375 - $386,305	106,128 Added 42.66%	354,928 $1.14 Million
Q2 2022 Aug 15, 2022	SELL	$1.9 - $3.98 $2,280 - $4,776	-1,200 Reduced 0.48%	248,800 $488,000
Q1 2022 May 16, 2022	SELL	$3.65 - $10.84 $24,163 - $71,760	-6,620 Reduced 2.58%	250,000 $1.01 Million
Q2 2021 Aug 16, 2021	BUY	$8.0 - $15.2 $291,872 - $554,556	36,484 Added 16.57%	256,620 $2.52 Million
Q2 2020 Aug 14, 2020	BUY	$0.72 - $16.76 $158,497 - $3.69 Million	220,136 New	220,136 $2.83 Million

128

67.3M

280K

76.3K

Ticker LRMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,269,200
Market Cap $174M
Description
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on 683 Capital Management, LLC with notifications on news.